Citations 1268
Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Mailankody, Sham , Matous, Jeffrey, Liedtke, Michaela , Sidana, Surbhi , Oluwole, Olalekan O. , Cruz, José C. , Nath, Rajneesh , Anwer, Faiz , Rossi, Adriana, Htut, Myo, Malik, Shahbaz A. , Ghatta, Srinivas, Dillon, Myles, Ying, Wendy , Navale, Lynn, Karski, Erin E., Balakumaran, Arun, Kumar, Shaji , Sidana, Surbhi , Oluwole, Olalekan O , Anwer, Faiz , Mohan, Meera , Rossi, Adriana , Htut, Myo
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4620-4622
Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma
Sharma, Neeraj , Tang, Hongwei , Yan, Huihuang , Tian, Shulan , Shivaram, Suganti, Kourelis, Taxiarchis , Kumar, Shaji , Sharma, Neeraj , Tang, Hongwei, Baughn, Linda B.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4209-4210
Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States
Mearns, Elizabeth S. , Nixon, Michael , Chopra, Vivek S. , Girvan, Allicia, Cornell, Robert F. , Saxena, Jayeta, Slifko, Bethany M., Clark, Jordan F. , Kumar, Shaji , Baughn, Linda B. , Slifko, Bethany Michelle, Clark, Jordan
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10114-10115
Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Kumar, Shaji , Plesner, Torben , Hulin, Cyrille , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Carson, Robin, Borgsten, Fredrik, Goldschmidt, Hartmut , Facon, Thierry T.F. , Weisel, Katja C , Usmani, Saad Z. , Moreau, Philippe , Orlowski, Robert Z. , Bahlis, Nizar Jacques , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Raje, Noopur , Frenzel, Laurent
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10133-10136
Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes
Kumar, Shaji , LaPlant, Betsy, Asmus, Erik, Thompson, Melanie , Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Buadi, Francis K. , Gonsalves, Wilson I. , Muchtar, Eli , Dingli, David , Thompson, Melanie Ann, Go, Ronald S. , Dispenzieri, Angela , Leung, Nelson , Binder, Moritz , Rajkumar, S. Vincent , Gertz, Morie A.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10142-10143
Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
Goel, Utkarsh , Charalampous, Charalampos , Kapoor, Prashant , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kourelis, Taxiarchis , Lacy, Martha Q. , Lin, Yi , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Binder, Moritz , Buadi, Francis K. , Dingli, David , Dispenzieri, Angela , Gertz, Morie A. , Gonsalves, Wilson I. , Leung, Nelson , Rajkumar, S. Vincent
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9998-9999
Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Plesner, Torben , Usmani, Saad Z. , Kumar, Shaji , Hulin, Cyrille , Roussel, Murielle , Delforge, Michel, Karlin, Lionel , Arnulf, Bertrand , Pei, Huiling , Gupta, Niodita, Kaila, Shuchita, Matt, Kathryn, Gries, Katharine S. , Carson, Robin, Borgsten, Fredrik, Usmani, Saad , Roussel, Murielle , Perrot, Aurore , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Jaccard, Arnaud , Chari, Ajai , Weisel, Katja C
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1142-1145
A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Allred, Jacob B., Kumar, Shaji , Costello, Brian A. , Gonsalves, Wilson I. , Neparidze, Natalia , Reid, Joel M. , Shapiro, Geoffrey I. , Piekarz, Richard , Baz, Rachid , Devarakonda, Srinivas
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7315-7316
Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib
Mulligan, George, Cook, April , Hamilton, Mark , Gnjatic, Sacha , Kumar, Shaji , Gnjatic, Sacha , Jayasinghe, Reyka G. , Cook, April, Kim-Schulze, Seunghee , Cho, Hearn Jay
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7090-7091
Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
Abdallah, Nadine , Nagayama, Hiroki , Fonder, Amie , Lacy, Martha Q. , Hobbs, Miriam, Kapoor, Prashant , Warsame, Rahma , Hayman, Suzanne R. , Kourelis, Taxiarchis , Hwa, Yi L., Kyle, Robert A. , Kumar, Shaji , Takahashi, Naoki , Gonsalves, Wilson I. , Dispenzieri, Angela , Dingli, David , Buadi, Francis K. , Gertz, Morie A. , Binder, Moritz , Lin, Yi , Rajkumar, S. Vincent , Broski, Stephen M.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7141-7143